If retatrutide were to receive regulatory approval in future, its pricing would likely be subject to negotiation between the manufacturer (Eli Lilly) and NHS England under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG, 2024), as well as appraisal by the National Institute for Health and Care Excellence (NICE) to determine cost-effectiveness
The escalation schedule exists because it works
The market remained relatively static until 2021 when Novo Nordisks semaglutide (Ozempic for diabetes and Wegovy for obesity) was approved, showing nearly 10% weight loss over two years
doi:10.1002/cam4.3345 Brenner, Meyer & Hostetter
3 Who can benefit from a B12 injection
Le Roith, D., Bondy, C., Yakar, S., Liu, J.-L., & Butler, A